# Discussing RA: Pain outcomes and drug effectiveness of JAK inhibitors in RA and PsA Page: https://stenobird.com/podcast/the-imid-forum-981476/discussing-ra-pain-outcomes-and-drug-effectiveness-of-jak-inhibitors-in-ra-and-psa Text version: https://stenobird.com/podcast/the-imid-forum-981476/discussing-ra-pain-outcomes-and-drug-effectiveness-of-jak-inhibitors-in-ra-and-psa.md Podcast: [The IMID Forum](https://stenobird.com/podcast/the-imid-forum-981476) Published: 2026-02-27T13:04:39+00:00 Episode link: https://soundcloud.com/imidforum/discussing-ra-pain-outcomes Audio file: https://feeds.soundcloud.com/stream/2273780474-imidforum-discussing-ra-pain-outcomes.mp3 Processing state: not_requested JSON: https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-ra-pain-outcomes-and-drug-effectiveness-of-jak-inhibitors-in-ra-and-psa Duration seconds: 518 ## Resource Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Taylor et al. where authors report the effects of UPA and ADA on pain in patients with active RA or PsA stratified by inflammatory status, and a paper by Sonomoto et al. which shows the effectiveness of TOF, BAR, UPA and FIL in patients with RA. ## Actions - request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-ra-pain-outcomes-and-drug-effectiveness-of-jak-inhibitors-in-ra-and-psa/transcription-requests` — Idempotently request low-priority transcript generation for this episode. - read_markdown: `GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-ra-pain-outcomes-and-drug-effectiveness-of-jak-inhibitors-in-ra-and-psa.md` — Read the agent-friendly Markdown representation of this episode resource. A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed. ## Transcript Full transcripts are not published on public pages unless there is a clear rights basis.